Humanigen, EVERSANA partner for launch of COVID-19 treatment, lenzilumab

Amidst umpteen COVID-19 treatment options and drugs being launched and commercialized worldwide, Humanigen and EVERSANA have partnered to launch a potential COVID-19 treatment- lenzilumab.

As per official sources, clinical-stage biopharmaceutical firm- Humanigen and a leading next-gen services provider to the global life sciences industry- EVERSANA have successfully inked a strategic partnership to make Humanigen’s leading drug candidate- lenzilumab feasible to hypoxic and hospitalized COVID-19 patients in case that an EUA (Emergency Use Authorization) is issued from the FDA and subsequent BLA.

For the record, lenzilumab is developed to prevent and treat cytokine storm, a major complication which is deemed to be a leading cause of fatality in COVID-19 patients.

It has been reported that under the terms of the partnership pact, Humanigen has attained an immediate access to EVERSANA’s fully integrated services including, marketing, medical education, medical data, health economics and outcomes research, marketing, and compliance and medical science liaison teams, with each service optimized by predictive analysis and data.

Moreover, the alliance with EVERSANA builds on the commercial preparation and drug launch planning the biopharma has been conducting over the past few months.

Speaking on the alliance, Cameron Durrant, MD, MBA, CEO of Humanigen, stated that the company is delighted to have reached the partnership terms with EVERSANA as the latter shares its tireless commitment to the patients.

He added that Humanigen has matched its dedication to R&D in COVID-19 with a proven commercialization partner to be assured that the lenzilumab reaches patients quickly and effectively following a potential Emergency Use Authorization.

Meanwhile, EVERSANA’s CEO- Jim Lang- cited that the firm is set to immediately activate its services encompassing all disciplines of the product journey to make sure that the drug candidate delivers significant patient values in relatively lesser time. Jim added that while the company’s model can be applied to any indication or therapy, it has a moral obligation to support COVID-19 patients in distress.

Source Credit:

By Shreya Bhute

With corporate exposure in software and marketing, Shreya was always intrigued by content development. Having pursued her graduation in I.T. engineering, she works as a content writer for and jots down news articles across distinct domains including technology, business and healthcare.